In the remaining 2 cases, infections occurred during/after treatment; IPA was the reason for death in one patient receiving first-line INF-α and the other patient died due to sepsis following frontline 2-CdA administration. This evidence concerns the gene IFNA17 and Ito hypomelanosis.